Thymoma patients treated in a phase I clinic at MD anderson cancer center: Responses to mTOR inhibitors and molecular analyses

Oncotarget

Volumn 4, Issue 6, 2013, Pages 890-898

  Wheler, Jennifer ^a   Hong, David ^a   Swisher, Stephen G ^a   Falchook, Gerald ^a   Tsimberidou, Apostolia M ^a   Helgason, Thorunn ^a   Naing, Aung ^a   Stephen, Bettzy ^a   Janku, Filip ^a   Stephens, Philip J ^b   Yelensky, Roman ^b   Kurzrock, Razelle ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Advanced thymoma; MTOR inhibitors; Response; Targeted therapy; Thymic carcinoma

Indexed keywords

ANTHRACYCLINE; ANTIMITOTIC AGENT; HISTONE DEACETYLASE INHIBITOR; IMMUNOMODULATING AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN RET; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CENTER; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG MECHANISM; FEMALE; GENE DELETION; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; MALE; MEDICAL RECORD; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SOMATIC MUTATION; THYMOMA; THYROID CARCINOMA; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THYMOMA; TOR SERINE-THREONINE KINASES; UNITED STATES;

EID: 84880780127     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1015     Document Type: Article

References (30)

1. Fornasiero A, Daniele O, Ghiotto C, Sartori F, Rea F, Piazza M, Fiore-Donati L, Morandi P, Aversa SM, Paccagnella A and et al. Chemotherapy of invasive thymoma. J Clin Oncol. 1990; 8(8):1419-1423.
2. Detterbeck FC and Parsons AM. Thymic tumors. Ann Thorac Surg. 2004; 77(5):1860-1869.
3. Strobel P, Hohenberger P and Marx A. Thymoma and thymic carcinoma: molecular pathology and targeted therapy. J Thorac Oncol. 2010; 5(10 Suppl 4):S286-290.
4. Chau NG, Kim ES and Wistuba I. The multidisciplinary approach to thymoma: combining molecular and clinical approaches. J Thorac Oncol. 2010; 5(10 Suppl 4):S313-317.
5. Kelly RJ, Petrini I, Rajan A, Wang Y and Giaccone G. Thymic malignancies: from clinical management to targeted therapies. J Clin Oncol. 2011; 29(36):4820-4827.
6. Girard N. Chemotherapy and targeted agents for thymic malignancies. Expert Rev Anticancer Ther. 2012; 12(5):685-695.
7. Girard N, Shen RL, Guo TH, Zakowski MF, Heguy A, Riely GJ, Huang J, Lau C, Lash AE, Ladanyi M, Viale A, Antonescu CR, Travis WD, Rusch VW, Kris MG and Pao W. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clinical Cancer Research. 2009; 15(22):6790-6799.
8. Nakagawa K, Matsuno Y, Kunitoh H, Maeshima A, Asamura H and Tsuchiya R. Immunohistochemical KIT (CD117) expression in thymic epithelial tumors. Chest. 2005; 128(1):140-144.
9. Petrini I, Meltzer PS, Zucali PA, Luo J, Lee C, Santoro A, Lee HS, Killian KJ, Wang Y, Tsokos M, Roncalli M, Steinberg SM and Giaccone G. Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors. Cell Death Dis. 2012; 3:e351.
10. Schmidt-Wolf IG, Rockstroh JK, Schuller H, Hirner A, Grohe C, Muller-Hermelink HK and Huhn D. Malignant thymoma: current status of classification and multimodality treatment. Ann Hematol. 2003; 82(2):69-76.
11. Palmieri G, Buonerba C, Federico P, Formisano L, Nappi L, Di Lorenzo G, Marino M and Damiano V. Everolimus plus long-acting somatostatin analogs in thymic epithelial malignancies. World J Clin Oncol. 2012; 3(7):111-115.
12. Seki Y, Yamamoto N, Tamura Y, Goto Y, Shibata T, Tanioka M, Asahina H, Nokihara H, Yamada Y, Shimamoto T, Noguchi K and Tamura T. Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012; 69(4):1099-1105.
13. Kondo K and Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg. 2003; 76(3):878-884; discussion 884-875.
14. Eng TY, Fuller CD, Jagirdar J, Bains Y and Thomas CR, Jr. Thymic carcinoma: state of the art review. Int J Radiat Oncol Biol Phys. 2004; 59(3):654-664.
15. Girard N. Thymic tumors: relevant molecular data in the clinic. J Thorac Oncol. 2010; 5(10 Suppl 4):S291-295.
16. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul SA, Naing A, Janku F, Luthra R, Ye Y, Wen S, Berry DA and Kurzrock R. Personalized Medicine in a Phase I Clinical Trials Program:The MD Anderson Cancer Center Initiative. Clin Cancer Res. 2012.
17. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366(10):883-892.
18. Christie M, Jorissen RN, Mouradov D, Sakthianandeswaren A, Li S, Day F, Tsui C, Lipton L, Desai J, Jones IT, McLaughlin S, Ward RL, Hawkins NJ, Ruszkiewicz AR, Moore J, Burgess AW, et al. Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/beta-catenin signalling thresholds for tumourigenesis. Oncogene. 2012.
19. Levine AJ and Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer. 2009; 9(10):749-758.
20. Wei G, Margolin AA, Haery L, Brown E, Cucolo L, Julian B, Shehata S, Kung AL, Beroukhim R and Golub TR. Chemical genomics identifies small-moleculeMCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell. 2012; 21(4):547-562.
21. Ruas M and Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta. 1998; 1378(2):F115-177.
22. Loehrer PJ, Sr., Chen M, Kim K, Aisner SC, Einhorn LH, Livingston R and Johnson D. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. J Clin Oncol. 1997; 15(9):3093-3099.
23. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S and Kurzrock R. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther. 2011; 10(3):558-565.
24. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH and Kurzrock R. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012; 30(8):777-782.
25. Zuo Z, Chen SS, Chandra PK, Galbincea JM, Soape M, Doan S, Barkoh BA, Koeppen H, Medeiros LJ and Luthra R. Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod Pathol. 2009; 22(8):1023-1031.
26. Sakr RA, Barbashina V, Morrogh M, Chandarlapaty S, Andrade VP, Arroyo CD, Olvera N and King TA. Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma. Appl Immunohistochem Mol Morphol. 2010; 18(4):371-374.
27. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-216.
28. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B and O'Dwyer PJ. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006; 24(16):2505-2512.
29. Kaplan EL and Meier P. Nonparametric estimation from incomplete observations Journal of the American Statistical Association 1958; 53(282):457-481.
30. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50(3):163-170.